Munich Personal RePEc Archive

Property Rights on Biodiversity and the Pharmaceutical Industry

Chichilnisky, Graciela (1993): Property Rights on Biodiversity and the Pharmaceutical Industry. Published in: (1993)

[img]
Preview
PDF
MPRA_paper_8330.pdf

Download (2879Kb) | Preview

Abstract

Major pharmaceutical companies such as Smith Kline Beecham, Merck, Glaxo and Lilly, and a score of smaller ones, are developing profitable business opportunities in the world's forest while preserving biodiversity and producing incentives for leaving the forests intact. This case study covers the business relationships between Merck and Co. and In Bio in Costa Rica, and the activities of Shaman Pharmaceuticals in Latin America and Africa. It provides the details, discusses what each party expects from these deals, and explores the connections with securitization and with issues of corporate responsibility towards the environment. The study explains the properties of externalities, which are typical of markets involving environmental assets, and the use of property rights in inducing efficient market solutions and corporate social responsibility.

UB_LMU-Logo
MPRA is a RePEc service hosted by
the Munich University Library in Germany.